Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45